Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar + Pembrolizumab + Chemo in First-Line Advanced NSCLC
NCT04094909Phase 2Unknown
- Sponsor
- Guangzhou Institute of Respiratory Health
- Start
- Feb 2020
- Primary completion
- Dec 2022
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of endostar in non-small cell lung cancer (NSCLC), sponsored by Guangzhou Institute of Respiratory Health. Status: unknown.
02
Drugs
endostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04094909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04094909.